Entering text into the input field will update the search result below

Pfizer and Astellas' Xtandi successful in late-stage prostate cancer study

Feb. 12, 2019 7:18 AM ETPfizer Inc. (PFE) Stock, ALPMF StockBy: Douglas W. House, SA News Editor4 Comments
  • Results from a Phase 3 clinical trial, ARCHES, evaluating Pfizer (NYSE:PFE) and Astellas Pharma's (OTCPK:ALPMF) XTANDI (enzalutamide) plus standard hormonal therapy in men with metastatic hormone-sensitive prostate cancer met the primary endpoint of demonstrating a statistically significant reduction in the risk radiographic progression or death by 61% compared to androgen deprivation therapy alone (hazard ratio = 0.39; p<0.0001). The data will be presented at the ASCO GU Cancers Symposium in San Francisco.
  • The companies plan to review the data with global regulatory authorities to support marketing applications for the new indication.

Recommended For You

Related Stocks

SymbolLast Price% Chg
PFE
--
ALPMF
--